{"product_id":"angiodynamics-bcg-matrix","title":"AngioDynamics Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuick snapshot: the AngioDynamics BCG Matrix teases which product lines are Stars, Cash Cows, Dogs or Question Marks—and where leadership should focus next. Want the full picture with quadrant-by-quadrant placements, data-backed recommendations, and tactical moves you can act on? Purchase the complete BCG Matrix for a ready-to-use Word report plus a high-level Excel summary—designed to save you hours and help you allocate capital with confidence. Buy now and get instant access to strategic clarity. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMechanical thrombectomy for venous\/arterial clot removal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMechanical thrombectomy sits in a high-growth endovascular market as VTE causes an estimated 100,000–300,000 US deaths annually (CDC) and peripheral artery disease affects ~237 million people globally, driving demand for minimally invasive, quick-turn procedures. AngioDynamics holds strong share in select thrombectomy niches and earns recurring disposable revenue, but it requires cash for sales coverage, clinical data, and training; current momentum supports continued investment to defend leadership and scale internationally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology ablation platforms (microwave, IRE-like energy)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInterventional oncology is expanding as payors and patients favor organ-sparing, image-guided treatments; the global tumor ablation market exceeded $2.0B in 2024 with ~6% CAGR driving adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmbolization tools for tumor and bleeding control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmbolization volumes are showing double-digit growth with wider IO adoption and updated trauma protocols, driving demand for precise, reliable delivery. AngioDynamics holds strong share inside targeted accounts, backed by a broad catheter and embolic lineup. Success requires continuous clinical education and field support, so cash in equals cash out for sustained preference. Investing now locks in physician preference and expands indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAtherectomy\/laser solutions for PAD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAtherectomy\/laser for PAD sits in Stars: global PAD prevalence exceeds 230 million, driving rising endovascular interventions and a clear shift toward outpatient\/ASC settings—favourable tailwinds for disposables where AngioDynamics is positioned.\u003c\/p\u003e\n\u003cp\u003eWhere present, AngioDynamics secures attractive disposable pull-through; competitive dynamics require ongoing capex, training, and head-to-head data to win accounts.\u003c\/p\u003e\n\u003cp\u003eRecommendation: invest to widen footprint and convert competitor accounts via targeted capital, clinical trials, and ASC partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket tag: PAD prevalence \u0026gt;230m (global)\u003c\/li\u003e\n\u003cli\u003eStrategy tag: invest in footprint, clinical data, ASC channel\u003c\/li\u003e\n\u003cli\u003eExecution tag: capex, training, convert competitor accounts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImage-guided access and therapy kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImage-guided access and therapy kits are Stars in AngioDynamics BCG matrix: packaged IR kits saw steady adoption with reported 2024 IR procedure volumes up about 7% year-over-year, attach rates exceeding 60% in core accounts, and kits driving double-digit revenue growth in bundled channels; strong field relationships and high per-case economics support durable share gains.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket growth: IR volumes +7% (2024)\u003c\/li\u003e\n\u003cli\u003eAttach rate: \u0026gt;60% in core accounts\u003c\/li\u003e\n\u003cli\u003eRevenue impact: double-digit growth in bundled channels (2024)\u003c\/li\u003e\n\u003cli\u003eNeeds: regular SKU refreshes and field education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvest in IR disposables: tumor ablation \u0026gt;$2B, IR volumes +7%, attach \u0026gt;60%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: thrombectomy, IO ablation, embolization, atherectomy and IR kits—2024 market tailwinds (VTE 100,000–300,000 US deaths; PAD ~237M; tumor ablation \u0026gt;$2.0B, ~6% CAGR) drive high-growth disposables, strong attach (\u0026gt;60%) and IR volumes +7% (2024); recommendation: invest in sales, trials, ASC partnerships to convert accounts and scale internationally.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTE deaths (US)\u003c\/td\u003e\n\u003ctd\u003e100,000–300,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAD prevalence\u003c\/td\u003e\n\u003ctd\u003e~237M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor ablation market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$2.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIR volumes YoY\u003c\/td\u003e\n\u003ctd\u003e+7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAttach rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG Matrix review of AngioDynamics' products, identifying Stars, Cash Cows, Question Marks and Dogs with strategic investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG view placing AngioDynamics units in quadrants to pinpoint issues and prioritize fixes fast\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAngiographic catheters and guide accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAngiographic catheters and guide accessories are mature, standardized products with entrenched preference in many IR labs, representing a stable cash stream (core-account share often exceeding 30%) and a dependable reorder cadence of roughly 4–8 weeks. Low promotional need preserves gross margins, typically above company averages, while these SKUs accounted for a substantial portion of recurring consumable revenue in 2024. Focus on manufacturing efficiency and supply-chain optimization to sustain cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlain angioplasty balloons and crossing tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePlain angioplasty balloons and crossing tools sit in a stable, slower-growth segment with clinicians following an established playbook and AngioDynamics benefiting from a solid installed base; the global angioplasty balloon market was roughly USD 1.6 billion in 2024. Predictable utilization drives steady cash flow and high gross margins, requiring minimal incremental marketing beyond tenders and pricing discipline. Milk politely—invest only to maintain reliability, service levels, and inventory availability to preserve cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVascular access disposables (PICC, ports, dialysis-related)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVascular access disposables (PICC, ports, dialysis-related) are cash cows for AngioDynamics: procedural volumes remain steady with established guidelines and sticky user habits, and the US dialysis population was about 550,000 patients in 2024 supporting predictable demand. Meaningful in-hospital share yields reliable gross profit with limited category innovation pressure versus high-growth tech. Focus is on efficiency, packaging and contract retention to protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrainage and biopsy needles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDrainage and biopsy needles are everyday IR staples—not glamorous but generating steady margins; AngioDynamics reported steady device revenues in 2024, with core consumables contributing a high-single-digit percent margin uplift to product-level results. Broad SKU coverage and deep distribution sustain volume; price sensitivity remains but quality and service create defensible repeat purchase economics. Keeping costs tight and service high preserves their cash-cow contribution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh repeat demand\u003c\/li\u003e\n\u003cli\u003eBroad SKU + distribution\u003c\/li\u003e\n\u003cli\u003ePrice-sensitive, service-defensible\u003c\/li\u003e\n\u003cli\u003eFocus: cost control + service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy RF ablation disposables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy RF ablation disposables form a mature oncology subsegment for AngioDynamics, with FY2024 reported revenue around $725 million company-wide and disposables driving stable recurring consumables demand; installed base utilization sustains repeat purchases even as newer energies gain traction. Minimal incremental R\u0026amp;D or marketing is required beyond reliability claims, so strategy is maintain, not overinvest—these SKUs fund operating cash flow. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base: stable repeat-procedure cohort\u003c\/li\u003e\n\u003cli\u003eRevenue role: steady recurring consumables income\u003c\/li\u003e\n\u003cli\u003eInvestment thesis: defend reliability, limit capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCatheters, balloons, disposables: steady margins, core share \u0026gt; \u003cstrong\u003e30%\u003c\/strong\u003e, focus cost \u0026amp; supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics cash cows—angiographic catheters, balloons, vascular access disposables, drainage needles, legacy RF disposables—deliver steady margins via high repeat demand, \u0026gt;30% core-account share and 4–8 week reorder cadence; FY2024 company revenue ~725M with balloon market ~$1.6B and ~550,000 US dialysis patients supporting volumes. Focus: cost control, supply efficiency, contract retention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 datapoint\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAngiographic catheters\u003c\/td\u003e\n\u003ctd\u003eCore share \u0026gt;30%\u003c\/td\u003e\n\u003ctd\u003eStable cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBalloons\u003c\/td\u003e\n\u003ctd\u003eMarket ~$1.6B\u003c\/td\u003e\n\u003ctd\u003eHigh-margin repeat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess disposables\u003c\/td\u003e\n\u003ctd\u003eUS dialysis ~550k\u003c\/td\u003e\n\u003ctd\u003eReliable revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eAngioDynamics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact AngioDynamics BCG Matrix you'll receive after purchase. No watermarks or demo content—just the finished, professionally formatted report ready for use. It includes market-backed analysis and editable slides so you can present or edit immediately. Buy once and download instantly—no surprises, no revisions needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-margin commodity catheters with heavy price pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLow-margin commodity catheters sit in a slow-growth market (low single-digit CAGR, under 3%), crowded with copycats and heavy GPO squeeze extracting roughly 20–30% concessions. Share is hard to grow and not worth the fight given saturated channels and rebate pressure. Cash is tied up in extensive SKU breadth that fails to move the needle. Recommend pruning lines or exiting unprofitable niches to free working capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder thrombolysis infusion sets displaced by thrombectomy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder thrombolysis infusion sets are classified as Dogs as procedure mix shifts toward faster mechanical thrombectomy; 2024 data show peripheral mechanical thrombectomy adoption rising while thrombolytic-only procedures fell to low single-digit growth. Market share is eroding as clinicians favor single-session devices that reduce OR time and length of stay. Turnarounds are costly with limited upside, so wind down SKUs and redeploy inventory capital to high-growth thrombectomy and single-session portfolios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche non-vascular tools with limited indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNiche non-vascular tools show small, stagnant demand in 2024 with limited global scalability; localized orders require disproportionate sales visits. Sales effort routinely outruns return and escalating support costs compress margins, creating a classic cash trap. They neither materially earn nor burn cash at scale, so divest or bundle selectively only where existing contracts mandate ongoing supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOverlapping SKUs with internal cannibalization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOverlapping SKUs create internal cannibalization at AngioDynamics: too many look-alike products confuse buyers, dilute volume, and keep growth flat while share fragments across the portfolio; this product complexity increases operational burden and compresses margins, so rationalizing to a smaller, higher-performing set is critical.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConfusion reduces unit economics\u003c\/li\u003e\n\u003cli\u003eFragmented share within portfolio\u003c\/li\u003e\n\u003cli\u003eHigher ops cost, margin pressure\u003c\/li\u003e\n\u003cli\u003eRationalize to fewer SKUs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographies with persistent reimbursement headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeographies with persistent reimbursement headwinds are low-growth markets where price caps and tender rules have compressed margins, leaving AngioDynamics with thin, volatile share and limited upside from further investment; by 2024 these regions remain structurally unattractive and unlikely to return acceptable ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePull back: prioritize profitable regions\u003c\/li\u003e\n\u003cli\u003eRedeploy capex to higher-margin markets\u003c\/li\u003e\n\u003cli\u003eAccept market exit where share \u003csmall\u003evolatile\u003c\/small\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrune low-margin catheters, redeploy into thrombectomy growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLow-margin commodity catheters and legacy thrombolysis sets are Dogs: market CAGR \u0026lt;3% (2024), GPO concessions 20–30%, thrombolytic-only procedures down ~2–3% in 2024 while mechanical thrombectomy adoption rose ~8–10% CAGR; SKU breadth ties cash and compresses margins. Niche non-vascular tools show flat demand; overlap cannibalizes share. Prune\/divest and redeploy to thrombectomy\/single-session portfolios.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eRecommended action\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommodity catheters\u003c\/td\u003e\n\u003ctd\u003eCAGR \u0026lt;3% \/ GPO 20–30% concessions\u003c\/td\u003e\n\u003ctd\u003ePrune SKUs, exit unprofitable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThrombolysis sets\u003c\/td\u003e\n\u003ctd\u003eProcedures -2–3% (2024)\u003c\/td\u003e\n\u003ctd\u003eWind down, redeploy capital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNiche non-vascular\u003c\/td\u003e\n\u003ctd\u003eFlat demand, low scale\u003c\/td\u003e\n\u003ctd\u003eDivest or bundle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverlap\/SKUs\u003c\/td\u003e\n\u003ctd\u003eHigh ops cost, fragmented share\u003c\/td\u003e\n\u003ctd\u003eRationalize portfolio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLow-return regions\u003c\/td\u003e\n\u003ctd\u003eReimbursement caps, volatile share\u003c\/td\u003e\n\u003ctd\u003ePull back\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-gen irreversible electroporation–type systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext-gen irreversible electroporation–type systems are high-growth clinical interest areas for AngioDynamics but remain a Question Mark as market share is still emerging and evidence-generation is costly. If pivotal clinical data and reimbursement broaden, this segment can flip to a Star; until then it consumes cash with uncertain near-term returns. Recommend selective bets on centers of excellence and targeted proof points to de-risk investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug-centric endovascular tech (e.g., drug-coated adjuncts)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDrug-centric endovascular tech faces ongoing legacy from the 2018 paclitaxel safety signal; 2024 clinical and real-world readouts have started to moderate that narrative but payer caution persists. Market share is low today with meaningful technical and regulatory hurdles to broad uptake. If adoption improves, attractive pull-through across AngioDynamics consumables could be unlocked. Invest cautiously and stage-gate spending based on clear clinical wins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobotics\/advanced navigation partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision-navigation and medical robotics show strong demand, with the global surgical\/medical robotics market growing ~13% CAGR to 2030 (MarketsandMarkets, 2024), but AngioDynamics’ role remains early-stage and share is minimal. Business model for platform-plus-disposables unproven; success could drive recurring disposable revenue. Recommend focused test pilots, rapid learning cycles and strict capex discipline—avoid overspend while validating use cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutpatient\/ASC-specific device bundles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOutpatient\/ASC-specific device bundles are a Question Mark for AngioDynamics: ASCs are booming—about 5,800 Medicare-certified ASCs in the US in 2024—but contracting and unit economics differ from hospitals, so market share remains nascent. If a bundle nails cost-to-value (targeting \u0026gt;20% procedure cost reduction), adoption can snowball. Success requires tailored kits, dedicated logistics, and ASC pricing. Fund pilots in high-volume regions and scale what sticks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eASC count: ~5,800 (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: tailored kits \u0026amp; logistics\u003c\/li\u003e\n\u003cli\u003ePricing: cost-to-value threshold critical\u003c\/li\u003e\n\u003cli\u003eStrategy: fund regional pilots, scale winners\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational expansion of IO portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternational expansion of the IO portfolio sits in Question Marks: many regions show rapid IO procedure growth (estimated mid-single-digit to high-single-digit CAGR in 2024), yet AngioDynamics’ market share remains low and variable, with upfront cash drains from registration, payer engagement, training, and distributor build-out; if reference sites and KOL adoption anchor, growth can inflect sharply, so prioritize markets with clear reimbursement and strong KOL pull.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003ePrioritize markets with reimbursement clarity and KOL networks\u003c\/li\u003e\n\u003cli\u003eExpect high upfront cash burn for regs, training, distributors\u003c\/li\u003e\n\u003cli\u003eReference-site wins can trigger rapid share gains\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 readouts could flip IRE \u0026amp; drug-devices; robotics pilots target 13% CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNext-gen IRE: high interest, low share; pivotal data + reimbursement could flip to Star. Paclitaxel-era drug devices: 2024 readouts moderating risk but uptake cautious. Robotics\/navigation: ~13% CAGR to 2030, AngioD share minimal. ASC bundles \u0026amp; IO international: ASCs ~5,800 (2024); pilots to de-risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Signal\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIRE\u003c\/td\u003e\n\u003ctd\u003eEarly trials\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003ctd\u003eSelective CE bets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug-devices\u003c\/td\u003e\n\u003ctd\u003eModerated risk\u003c\/td\u003e\n\u003ctd\u003eConstrained uptake\u003c\/td\u003e\n\u003ctd\u003eStage-gate spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobotics\u003c\/td\u003e\n\u003ctd\u003e13% CAGR\u003c\/td\u003e\n\u003ctd\u003eMinimal share\u003c\/td\u003e\n\u003ctd\u003ePilot programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCs\/IO Intl\u003c\/td\u003e\n\u003ctd\u003eASCs 5,800\u003c\/td\u003e\n\u003ctd\u003eNascent\u003c\/td\u003e\n\u003ctd\u003eRegional pilots\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097797726556,"sku":"angiodynamics-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/angiodynamics-bcg-matrix.png?v=1781788245","url":"https:\/\/pestel-analysis.com\/products\/angiodynamics-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}